BioSpace News Archive

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the U.S. Food and Drug Administration (FDA) has approved TEPEZZATM (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED). TEPEZZA is the first and only FDA-approved medicine for the treatment of TED

Cell>Point announced, based on its sponsored chelator and therapeutic research conducted at the University of Texas M.D. Anderson Cancer Center on Platinum-Oncardia and 177Lu-Oncardia, and the positive results of its lung cancer imaging trials with 99mTc-Oncardia®, that it will be moving forward with these two intra-nuclear therapeutics expanding its focus in theranostic medicine.

Shockwave Medical, Inc., a pioneer in the development and commercialization of Intravascular Lithotripsy to treat complex calcified cardiovascular disease, announced it will report financial results for the fourth quarter and full year 2019 after market close on Thursday, February 13, 2020.

Sol-Gel Technologies Ltd. announced the presentation of results from the Company’s Phase 3 trials for its candidates Epsolay® for the treatment of moderate-to-severe papulopustular rosacea and Twyneo® for the treatment of moderate-to-severe acne vulgaris.

Blueprint Medicines Corporation, a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, announced that it has commenced an underwritten public offering of $325,000,000 in shares of its common stock.

Avantor, Inc. announced that its Board of Directors has declared a quarterly cash dividend to holders of its 6.250% Series A Mandatory Convertible Preferred Stock of $0.78 per share at a rate per share of 1.560%, payable on February 15, 2020 to holders of record on February 1, 2020.

Vertex Pharmaceuticals Incorporated will report its full-year and fourth-quarter 2019 financial results on Thursday, January 30, 2020 after the financial markets close.

The Marchand Institute for Minimally Invasive Surgery released a warning regarding new lines of small adult toys that are marketed as being as wearable as fashion jewelry and doubling as a functioning vibrating adult toy.

Ncardia and BlueRock Therapeutics today announced an agreement covering process development technologies for the manufacture of induced pluripotent stem cell (iPSC)-derived cardiomyocytes.

REVIAN Inc. (formerly PhotonMD Inc.) – a medical technology company dedicated to stimulating the body’s natural processes to rejuvenate hair and skin with light – is excited to announce that final data from a randomized, double-blind study of the REVIAN RED hair growth system was presented at the 2020 Winter Clinical Dermatology Conference - Hawaii®.